Cited by 1,308Cancer-related Molecular PathwaysChromatin Remodeling and CancerPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 57 of the 64 references it cites were found in a registry or an index.

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Open access

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell

DOI 10.1016/j.cell.2004.11.004

Open this paper in CoChat — free account Open PDF

Abstract

The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through missense mutations that result in accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological effects of p53 point mutation, the structural mutant p53R172H and the contact mutant p53R270H (codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice. p53R270H/+ and p53R172H/+ mice are models of Li-Fraumeni Syndrome; they developed allele-specific tumor spectra distinct from p53+/- mice. In addition, p53R270H/- and p53R172H/- mice developed novel tumors compared to p53-/- mice, including a variety of carcinomas and more frequent endothelial tumors. Dominant effects that varied by allele and function were observed in primary cells derived from p53R270H/+ and p53R172H/+ mice. These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2004.11.004

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINES
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities
Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,118
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065
p73 is a human p53-related protein that can induce apoptosis
Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Self-citation
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., & Rotter, V. (1984) · Nature · doi:10.1038/312649a0 · Cited by 734
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.
DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
Eliyahu, D., Raz, A., Gruß, P., Givol, D., & Oren, M. (1984) · Nature · doi:10.1038/312646a0 · Cited by 720
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M. S., Marín, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Cre-lox-regulated conditional RNA interference from transgenes
Ventura, A., Meissner, A., Dillon, C. P., McManus, M. T., Sharp, P. A., Parijs, L. V., Jaenisch, R., & Jacks, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403954101 · Cited by 623
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation
Hinds, P. W., Finlay, C. A., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 595
A subset of p53-deficient embryos exhibit exencephaly
Sah, V. P., Attardi, L. D., Mulligan, G., Williams, B. O., Bronson, R. T., & Jacks, T. (1995) · Nature Genetics · doi:10.1038/ng0695-175 · Cited by 594
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511
Untitled work
(1994) · PubMed · Cited by 509
AIS is an oncogene amplified in squamous cell carcinoma
Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., Ratovitski, E. A., Jen, J., & Sidransky, D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5462 · Cited by 464
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells
O’Gorman, S., Dagenais, N., Qian, M., & Marchuk, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14602 · Cited by 436
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Como, C. J. D., Gaiddon, C., & Prives, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Tumors associated with p53 germline mutations: a synopsis of 91 families.
Kleihues, P., Schäuble, B., Hausen, A. Z., Estève, J., & Ohgaki, H. (1997) · Europe PMC (PubMed Central) · Cited by 413
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408
High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene
Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T. J., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 393
Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.
Purdie, C. A., Harrison, D. J., Peter, A., Dobbie, L., White, S., Howie, S., Salter, D. M., Bird, C., Wyllie, A. H., & Hooper, M. L. (1994) · PubMed · Cited by 290
Monoclonal antibody analysis of p53 expression in normal and transformed cells
Yewdell, J. W., Gannon, J., & Lane, D. P. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.444-452.1986 · Cited by 261
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice
Harvey, M., Vogel, H. S., Morris, D. K., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 232
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth
Cadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 231
Germline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk
Hwang, S., Lozano, G., Amos, C. I., & Strong, L. C. (2003) · The American Journal of Human Genetics · doi:10.1086/374567 · Cited by 229
Clinical implications of p53 mutations
Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050270 · Cited by 226
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function
de Vries, A., Flores, E. R., Miranda, B., Hsieh, H.-M., van Oostrom, C. T. M., Sage, J., & Jacks, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052713099 · Cited by 207
High metastatic potential in mice inheriting a targeted p53 missense mutation
Liu, G., McDonnell, T. J., Luna, R. M. D. O., Kapoor, M., Mims, B. H., El‐Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 201
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
Development of Spontaneous Mammary Tumors in BALB/c p53 Heterozygous Mice
Kuperwasser, C., Hurlbut, G. D., Kittrell, F. S., Dickinson, E. S., Laucirica, R., Medina, D., Naber, S. P., & Jerry, D. J. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64853-5 · Cited by 188
Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients
Casciano, I., Mazzocco, K., Boni, L., Pagnan, G., Banelli, B., Allemanni, G., Ponzoni, M., Tonini, G., & Romani, M. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400993 · Cited by 181
Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.
Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P. K., Yeargin, J., & Haas, M. (1994) · PubMed Central · Cited by 135
Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
Shaulsky, G., Goldfinger, N., & Rotter, V. (1991) · PubMed · Cited by 132
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene
Zhou, M., Yeager, A., Smith, S. D., & Findley, H. W. (1995) · Blood · doi:10.1182/blood.v85.6.1608.bloodjournal8561608 · Cited by 129
Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., & Harris, C. C. (1995) · PubMed · Cited by 100
A transgenic mouse model for mammary carcinogenesis
Li, B., Murphy, K. L., Laucirica, R., Kittrell, F. S., Medina, D., & Rosen, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201621 · Cited by 89
Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis
Wang, X., Greenhalgh, D. A., Jiang, A., He, D., Zhong, L., Medina, D., Brinkley, B. R., & Roop, D. R. (1998) · Oncogene · doi:10.1038/sj.onc.1201890 · Cited by 85
p53 Mutants Have Selective Dominant-Negative Effects on Apoptosis but Not Growth Arrest in Human Cancer Cell Lines
Aurelio, O. N., Kong, X., Gupta, S., & Stanbridge, E. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.770-778.2000 · Cited by 75
The effect of environmental cues on the differentiation of myofibroblasts in peritoneal granulation tissue
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response
PELLER, S. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0100 · Cited by 54
mdm-2 expression in human testicular germ-cell tumors and its clinical value.
Eid, H., Institóris, E., Géczi, L., Bodrogi, I., & Bak, M. (1999) · PubMed · Cited by 23

Flagged first, then by citations

7 of the 64 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Hinds, 1990, Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells, Cell Growth Differ, 1, 571
Kleihues, 1997, Tumors associated with p53 germline mutations, Am. J. Pathol, 150, 1

Sorted by citations

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
p53 in health and disease
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351

See all 1,308

Authors: Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T.
Affiliations: Massachusetts Institute of Technology (US)
Abramson Cancer Center (US)
Tufts University (US)
Howard Hughes Medical Institute (US)
Corresponding author: Jacks, Tyler
ORCID: Olive, Kenneth P.
Tuveson, David A.
Ruhe, Zachary C.
Willis, Nicholas A.
Bronson, Roderick T.
Jacks, Tyler
Venue: Cell
Publisher: Elsevier BV
Published: 2004-12
Volume: 119
Issue: 6
Pages: 847-860
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2004.11.004
OpenAlex: W2079852484
Cited by: 1,308
References: 64
Citations by year: 2026: 26 · 2025: 49 · 2024: 52 · 2023: 87 · 2022: 52 · 2021: 64 · 2020: 67 · 2019: 69 · 2018: 74 · 2017: 69 · 2016: 78 · 2015: 75 · 2014: 97 · 2013: 64 · 2012: 51
FWCI: 21.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3150 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, Li-Fraumeni syndrome, gain-of-function mutations, missense mutations, dominant-negative p53, tumor suppressor, mouse model, endothelial tumors, carcinoma, oncogenicity
MeSH terms: Alleles, Animals, Carcinoma, Mice, Transgenic, Mutation, Neoplasms, T-Lymphocytes, Gene Expression Regulation, Neoplastic, Genes, p53, Li-Fraumeni Syndrome, Apoptosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks